Diagnosis and treatment of chronic acquired demyelinating polyneuropathies, Nat Rev Neurol, vol.10, pp.435-481, 2014. ,
Neuropathy associated with "benign" anti-myelin-associated glycoprotein IgM gammopathy: clinical, immunological, neurophysiological pathological findings and response to treatment in 33 cases, J Neurol, vol.243, pp.34-43, 1996. ,
Prognosis of polyneuropathy due to IgM monoclonal gammopathy: a prospective cohort study, Neurology, vol.74, pp.406-418, 2010. ,
Immunotherapy-based regimen in anti-MAG neuropathy: results in 45 patients, Haematologica, vol.98, pp.155-162, 2013. ,
Long-term prognosis of neuropathy associated with anti-MAG IgM M-proteins and its relationship to immune therapies, Brain, vol.123, pp.710-717, 2000. ,
Recent advances in outcome measures in IgM-antiMAG+ neuropathies, Curr Opin Neurol, vol.28, pp.486-93, 2015. ,
, European Federation of Neurological Societies/Peripheral Nerve Society Guideline on management of paraproteinemic demyelinating neuropathies, Joint Task Force of the EFNS and the PNS, vol.15, pp.185-95, 2010.
Anti-myelin-associated glycoprotein antibodies alter neurofilament spacing, Brain, vol.125, pp.904-915, 2002. ,
Experimental demyelination of nerve induced by serum of patients with neuropathy and an anti-MAG IgM M-protein, Neurology, vol.37, pp.242-56, 1987. ,
Peripheral neuropathy in macroglobulinemia: incidence and antigen-specificity of M proteins, Neurology, vol.37, pp.1506-1520, 1987. ,
Morphological changes at paranodes in IgM paraproteinaemic neuropathy, Microsc Res Tech, vol.34, pp.544-53, 1996. ,
Oncogenically active MYD88 mutations in human lymphoma, Nature, vol.470, pp.115-124, 2011. ,
MYD88 L265P somatic mutation in Waldenström's macroglobulinemia, N Engl J Med, vol.367, pp.826-859, 2012. ,
MYD88 L265P somatic mutation in IgM MGUS, N Engl J Med, vol.367, pp.2256-2263, 2012. ,
MYD88 (L265P) mutation is an independent risk factor for progression in patients with IgM monoclonal gammopathy of undetermined significance, Blood, vol.122, pp.2284-2289, 2013. ,
MYD88 L265P in Waldenström macroglobulinemia, immunoglobulin M monoclonal gammopathy, and other B-cell lymphoproliferative disorders using conventional and quantitative allele-specific polymerase chain reaction, Blood, vol.121, pp.2051-2059, 2013. ,
Regulation of CXCR4 signaling, Biochim Biophys Acta, vol.1768, pp.952-63, 2007. ,
Site-specific phosphorylation of CXCR4 is dynamically regulated by multiple kinases and results in differential modulation of CXCR4 signaling, J Biol Chem, vol.285, pp.7805-7822, 2010. ,
The genomic landscape of Waldenstrom macroglobulinemia is characterized by highly recurring MYD88 and WHIM-like CXCR4 mutations, and small somatic deletions associated with B-cell lymphomagenesis, Blood, vol.123, pp.1637-1683, 2014. ,
Somatic mutations in MYD88 and CXCR4 are determinants of clinical presentation and overall survival in Waldenstrom macroglobulinemia, Blood, vol.123, pp.2791-2797, 2014. ,
Clinical and genetic features of Warts, Hypogammaglobulinemia, Infections and Myelokathexis (WHIM) syndrome, Curr Mol Med, vol.11, pp.317-342, 2011. ,
Chromosomal aberrations and their prognostic value in a series of 174 untreated patients with Waldenström's macroglobulinemia, Haematologica, vol.98, pp.649-54, 2013. ,
SF3B1 and other novel cancer genes in chronic lymphocytic leukemia, N Engl J Med, vol.365, pp.2497-506, 2011. ,
Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia, Nature, vol.475, pp.101-106, 2011. ,
Presence of multiple recurrent mutations confers poor trial outcome of relapsed/refractory CLL, Blood, vol.126, pp.2110-2117, 2015. ,
WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications, Blood, vol.117, pp.5019-5051, 2008. ,
Clinicopathological definition of Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia, Semin Oncol, vol.30, pp.110-115, 2003. ,
The 2016 revision of the World Health Organization classification of lymphoid neoplasms, Blood, vol.127, pp.2375-90, 2016. ,
URL : https://hal.archives-ouvertes.fr/hal-01800015
The human genome browser at UCSC, Genome Res, vol.12, pp.996-1006, 2002. ,
COSMIC: exploring the world's knowledge of somatic mutations in human cancer, Nucleic Acids Res, vol.43, pp.805-816, 2015. ,
Analysis of protein-coding genetic variation in 60,706 humans, Nature, vol.536, pp.285-91, 2016. ,
A method and server for predicting damaging missense mutations, Nat Methods, vol.7, pp.248-257, 2010. ,
SIFT: Predicting amino acid changes that affect protein function, Nucleic Acids Res, vol.31, pp.3812-3816, 2003. ,
Placebo-controlled trial of rituximab in IgM anti-myelinassociated glycoprotein neuropathy, Neurology, vol.80, pp.2217-2242, 2013. ,
Heterogeneity of Polyneuropathy Associated with Anti-MAG Antibodies, J Immunol Res, p.450391, 2015. ,
Detection of MYD88 L265P in peripheral blood of patients with Waldenström's Macroglobulinemia and IgM monoclonal gammopathy of undetermined significance, Leukemia, vol.28, pp.1698-704, 2014. ,
MYD88 L265P is a marker highly characteristic of, but not restricted to, Waldenström's macroglobulinemia, Leukemia, vol.27, pp.1722-1730, 2013. ,
MYD88 L265P mutation in Waldenstrom macroglobulinemia, Blood, vol.121, pp.4504-4515, 2013. ,
MYD88 L265P and CXCR4 mutations in lymphoplasmacytic lymphoma identify cases with high disease activity, Br J Haematol, vol.169, pp.795-803, 2015. ,
ATM deficiency promotes development of murine B-cell lymphomas that resemble diffuse large B-cell lymphoma in humans, Blood, vol.126, pp.2291-301, 2015. ,
ATM mutations are associated with inactivation of the ARF-TP53 tumor suppressor pathway in diffuse large B-cell lymphoma, Blood, vol.100, pp.1430-1437, 2002. ,
Somatic ATM mutations indicate a pathogenic role of ATM in B-cell chronic lymphocytic leukemia, Blood, vol.94, pp.748-53, 1999. ,
Mutations in the ATM gene lead to impaired overall and treatment-free survival that is independent of IGVH mutation status in patients with B-CLL, Blood, vol.106, pp.3175-82, 2005. ,
ATM germline heterozygosity does not play a role in chronic lymphocytic leukemia initiation but influences rapid disease progression through loss of the remaining ATM allele, Haematologica, vol.97, pp.142-148, 2012. ,
Clinical impact of clonal and subclonal TP53, SF3B1, BIRC3, NOTCH1, and ATM mutations in chronic lymphocytic leukemia, Blood, vol.127, pp.2122-2152, 2016. ,
Does wild-type p53 play a role in normal cell differentiation?, Semin Cancer Biol, vol.5, pp.229-265, 1994. ,
Regulation of specific DNA binding by p53: evidence for a role for O-glycosylation and charged residues at the carboxy-terminus, Oncogene, vol.12, pp.921-951, 1996. ,
Cellular senescence and cancer, J Pathol, vol.187, pp.100-111, 1999. ,
Modes of p53 regulation, Cell, vol.137, pp.609-631, 2009. ,
The clinical significance of mutations of the P53 tumour suppressor gene in haematological malignancies, Br J Haematol, vol.98, pp.502-513, 1997. ,
Mutations in the p53 Tumor Suppressor Gene: Important Milestones at the Various Steps of Tumorigenesis, Genes Cancer, vol.2, pp.466-74, 2011. ,
New mutations and pathogenesis of myeloproliferative neoplasms, Blood, vol.118, pp.1723-1758, 2011. ,
Spliceosome mutations in hematopoietic malignancies, Nat Genet, vol.44, pp.9-10, 2012. ,
Chronic lymphocytic leukemia with SF3B1 mutation, N Engl J Med, vol.366, p.2530, 2012. ,
Exome sequencing identifies recurrent mutations of the splicing factor SF3B1 gene in chronic lymphocytic leukemia, Nat Genet, vol.44, pp.47-52, 2012. ,
The clinical significance of NOTCH1 and SF3B1 mutations in the UK LRF CLL4 trial, Blood, vol.121, pp.468-75, 2013. ,
Constitutive activation of NF-kappaB and T-cell leukemia/lymphoma in Notch3 transgenic mice, EMBO J, vol.19, pp.3337-3385, 2000. ,
Mutations of the Notch1 gene in T-cell acute lymphoblastic leukemia: analysis in adults and children, Leukemia, vol.19, pp.1841-1844, 2005. ,
Constitutively activated Notch signaling is involved in survival and apoptosis resistance of B-CLL cells, Blood, vol.113, pp.856-65, 2009. ,
New boys in town: prognostic role of SF3B1, NOTCH1 and other cryptic alterations in chronic lymphocytic leukemia and how it works, Leuk Lymphoma, vol.54, pp.1876-81, 2013. ,
Trisomy 12 CLLs progress through NOTCH1 mutations, Leukemia, vol.27, pp.740-743, 2013. ,
DOI : 10.1038/leu.2012.239
URL : http://europepmc.org/articles/pmc3733494?pdf=render
p53 and Notch signaling in chronic lymphocytic leukemia: clues to identifying novel therapeutic strategies, Leukemia, vol.25, pp.1400-1407, 2011. ,
DOI : 10.1038/leu.2011.103
URL : http://www.nature.com/leu/journal/v25/n9/pdf/leu2011103a.pdf
Bone marrow biopsy involvement by non-Hodgkin's lymphoma: frequency of lymphoma types, patterns, blood involvement, and discordance with other sites in 450 specimens, Am J Surg Pathol, vol.29, pp.1549-57, 2005. ,
Bone marrow trephine biopsy involvement by lymphoma: review of histopathological features in 511 specimens and correlation with diagnostic biopsy, aspirate and peripheral blood findings, J Clin Pathol, vol.67, pp.389-95, 2014. ,
Detection of MYD88 L265P in peripheral blood of patients with Waldenström's Macroglobulinemia and IgM monoclonal gammopathy of undetermined significance, Leukemia, vol.28, pp.1698-704, 2014. ,
C1013G/CXCR4 acts as a driver mutation of tumor progression and modulator of drug resistance in lymphoplasmacytic lymphoma, Blood, vol.123, pp.4120-4151, 2014. ,
Clonal architecture of CXCR4 WHIM-like mutations in Waldenström Macroglobulinaemia, Br J Haematol, vol.172, pp.735-779, 2016. ,
How useful are anti-neural IgM antibodies in the diagnosis of chronic immune-mediated neuropathies?, J Neurol Sci, vol.266, pp.156-63, 2008. ,
Epidemiology of chronic inflammatory neuropathies in southeast England, Eur J Neurol, vol.21, pp.28-33, 2014. ,
Immunotherapy for IgM anti-myelin-associated glycoprotein paraprotein-associated peripheral neuropathies, Cochrane Database Syst Rev, p.2827, 2012. ,
DOI : 10.1002/14651858.cd002827
URL : https://air.unimi.it/bitstream/2434/481190/2/LunnNobileOrazio_TheCochraneLibrary_ImmunotherapyIgM_2016.pdf
Structure, function and regulation of the Toll/IL-1 receptor adaptor proteins, Immunol Cell Biol, vol.85, pp.411-420, 2007. ,
Identification of critical residues of the MyD88 death domain involved in the recruitment of downstream kinases, J Biol Chem, vol.284, pp.28093-103, 2009. ,
Helical assembly in the MyD88-IRAK4-IRAK2 complex in TLR/IL-1R signalling, Nature, vol.465, pp.885-90, 2010. ,
A mutation in MYD88 (L265P) supports the survival of lymphoplasmacytic cells by activation of Bruton tyrosine kinase in Waldenström macroglobulinemia, Blood, vol.122, pp.1222-1254, 2013. ,
The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy, Proc Natl Acad Sci, vol.107, pp.13075-80, 2010. ,
Ibrutinib in previously treated Waldenström's macroglobulinemia, N Engl J Med, vol.372, pp.1430-1470, 2015. ,
DOI : 10.1056/nejmoa1501548